Document Detail

Longer Intervals Between Hematopoietic Stem Cell Transplantation and Subsequent 90Y-Ibritumomab Radioimmunotherapy May Correlate With Better Tolerance.
MedLine Citation:
PMID:  22955069     Owner:  NLM     Status:  In-Data-Review    
PURPOSE: This study aimed to evaluate the efficacy and toxicity of radioimmunotherapy (RIT) in recurrent lymphoma after hematopoietic stem cell transplantation (HSCT).
METHODS: We reviewed 9 patients, 7 with follicular lymphoma (DLBCL), 1 with mantle cell lymphoma (MCL), and 1 with diffuse large B-cell lymphoma treated with Y-ibritumomab tiuxetan 6 to 140 months after HSCT. Patients underwent In-ibritumomab scintigraphy and were treated 1 week later with standard 14.8 MBq/kg (n = 4) or 11.1 MBq/kg (n = 4) Y-ibritumomab. One patient who had allo-HSCT had reduced activity (70%) treatment.
RESULTS: Among the 7 FL patients, we observed complete response (CR) in 2 patients and partial response (PR) in 5 patients. One patient with CR relapsed after 15 months; the other persisted 43.5 months after RIT. Of 5 patients with PR, 3 relapsed between 13 and 17 months; 1 persisted until unrelated death at 11.5 months. The fifth patient with PR received adoptive immunotherapy and improved to metabolic (FDG-PET) CR that persists 45.5 and 41 months after Y-ibritumomab and immunotherapy, respectively. Patients with MCL and DLBCL progressed or experienced stabilization (5 months), respectively. Six patients had grade 1 to 3 bone marrow (BM) toxicity and recovered within 3 months. Three patients having Y-ibritumomab 6, 14, and 24 months after HSCT experienced grade 4 BM toxicity. One of them (RIT 24 months after HSCT) recovered after 3 months, another delayed after 9 months, and the third patient only partially recovered, eventually developed myelodysplasia, and was allografted.
CONCLUSIONS: Radioimmunotherapy after HSCT is an effective rescue therapy in FL. However, BM toxicity may be important; 3 of 8 patients treated with standard Y-ibritumomab activity experienced grade 4 BM toxicity, with incomplete recovery 3 months after RIT in 2 patients, both treated early (6 and 14 months) after HSCT.
Franz Buchegger; John O Prior; Gilles Allenbach; Sébastien Baechler; Marek Kosinski; Claudine Helg; Yves Chalandon; Osman Ratib; Angelika Bischof Delaloye; Nicolas Ketterer
Related Documents :
23326979 - Minimally invasive and standard total knee arthroplasty result in similar clinical outc...
24040949 - Temporomandibular joint condylar changes following maxillomandibular advancement and ar...
23702009 - A 3-center comparison of 1-year mortality outcomes between transcatheter aortic valve i...
22219419 - Midterm follow-up dynamic echocardiography evaluation after ascending aorta replacement...
23481699 - Coracoid bone block versus arthroscopic bankart repair: a comparative paired study with...
19239459 - Incidentally discovered renal masses: oncological and perioperative outcomes in patient...
20869839 - Early changes of procalcitonin may advise about prognosis and appropriateness of antimi...
21989129 - Loss of normal knee motion after anterior cruciate ligament reconstruction is associate...
25248319 - Effect of different surgical options on curative effect, nutrition, and health status o...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical nuclear medicine     Volume:  37     ISSN:  1536-0229     ISO Abbreviation:  Clin Nucl Med     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7611109     Medline TA:  Clin Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  960-4     Citation Subset:  IM    
From the *Department of Nuclear Medicine, University Hospital of Geneva, Geneva; and †Department of Nuclear Medicine and ‡Institute of Radiation Physics, Centre Hospitalier Universitaire and University of Lausanne, Lausanne; §Medical Oncology, Clinic of Genolier, Genolier; ∥Division of Hematology, University Hospital of Geneva, Geneva; and ¶Multidisciplinary Oncology Center, Centre Hospitalier Universitaire and University of Lausanne, Lausanne, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  18F-FDG Uptake Changes in Liver and Mediastinum During Chemotherapy in Patients With Diffuse Large B...
Next Document:  Relationship Between Myocardial Perfusion-Gated SPECT and the Performance of Coronary Revascularizat...